Unknown

Dataset Information

0

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis.

ABSTRACT:

SUBMITTER: Sousos N 

PROVIDER: S-EPMC7306308 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy.
| S-EPMC7495781 | biostudies-literature
Unknown Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
| S-EPMC6237652 | biostudies-literature
Unknown Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
| S-EPMC5256142 | biostudies-literature
Unknown Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.
| S-EPMC5695391 | biostudies-literature
Unknown Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.
| S-EPMC4103574 | biostudies-other
Unknown Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
| S-EPMC4722809 | biostudies-other
Unknown Duvelisib: a phosphoinositide-3 kinase ?/? inhibitor for chronic lymphocytic leukemia.
| S-EPMC5584596 | biostudies-literature
Unknown JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.
| S-EPMC4741449 | biostudies-literature
Unknown Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.
| S-EPMC6324680 | biostudies-literature
Unknown Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
| S-EPMC4979099 | biostudies-literature